TheraKine and Cell Care Therapeutics Enter into License and Development Agreement

Privately held TheraKine, Ltd., and Cell Care Therapeutics, Inc, entered into a licensing agreement to use TheraKine’s injectable sustained release technology to enable Cell Care’s stem cell therapies for diseases of the eye that commonly cause blindness.
Nicolas Sohl, CEO of Cell Care commented:

It gives us all confidence to know that the effects of our proprietary regenerative therapies can be extended to many months in order to direct neuro-vascular repair and treat chronic inflammatory and degenerative ocular diseases over a clinically relevant period of time. We hope that we will soon be in human studies to help prevent otherwise incurable conditions that leave people blind or disabled.

Seth Yakatan, CEO of TheraKine, stated:

It is very exciting being part of the solution to enable many months of therapy with stem cells, using technologies we originally developed for antibodies, especially since stem cells show promise as the future of therapy for many difficult diseases.

Click here to view the full press release.